1. "Radiotherapy for thymic epithelial tumors: What is the optimal dose? A systematic review.". (May 2022) Authors: Angrisani, A.; Houben, R.; Marcuse, F.; Hochstenbag, M.; Maessen, J.; De Ruysscher, D.; Peeters, S. Journal: Clinical and translational radiation oncology Issue: Volume 34(2022) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 143: The management of patients with extensive-stage small-cell lung cancer: A European survey of practice. (January 2017) Authors: Haslett, K.; De Ruysscher, D.; Dziadziuszko, R.; Guckenberger, M.; Le Pechoux, C.; Nestle, U.; Slotman, B.; Faivre-Finn, C. Journal: Lung cancer Issue: Volume 103(2017)Supplement 1 Page Start: S64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Acute toxicity and quality of life in breast cancer patients treated by radiotherapy – results from the REQUITE multi-centre cohort study. (April 2018) Authors: Rattay, T.; Johnson, K.; Azria, D.; Chang-Claude, J.; Davidson, S.; Dunning, A.; De Ruysscher, D.; Gutierrez-Enriquez, S.; Lambin, P.; Rancati, T.; Rosenstein, B.; Seibold, P.; Symonds, R.P.; Valdagni, R.; Vega, A.; Veldeman, L.; Webb, A.; Wenz, F.; West, C.; Talbot, C. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10 years of follow up. Issue 1 (January 2018) Authors: Brouwers, P.J.A.M.; van Loon, J.; Houben, R.M.A.; Paulissen, J.; Engelen, S.M.E.; Heuts, M.; de Boer, M.; Verhoeven, K.; De Ruysscher, D.; Boersma, L.J. Journal: Radiotherapy and oncology Issue: Volume 126:Issue 1(2018) Page Start: 163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts. (August 2020) Authors: Früh, M.; Panje, C.M.; Reck, M.; Blackhall, F.; Califano, R.; Cappuzzo, F.; Besse, B.; Novello, S.; Garrido, P.; Felip, E.; O'Brien, M.; Paz Ares, L.; de Marinis, F.; Westeel, V.; De Ruysscher, D.; Putora, P.M. Journal: Lung cancer Issue: Volume 146(2020) Page Start: 6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Early variation of FDG-PET radiomics features in NSCLC is related to overall survival - the "delta radiomics" concept. (15th February 2016) Authors: Carvalho, S.; Leijenaar, R.T.H.; Troost, E.G.C.; van Elmpt, W.; Muratet, J.-P.; Denis, F.; De Ruysscher, D.; Aerts, H.J.W.L.; Lambin, P. Journal: Radiotherapy and oncology Issue: Volume 118(2016)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. EP-1237: Heart dose as a risk factor for dyspnea worsening after multimodality treatment for NSCLC and MPM. (May 2017) Authors: Botticella, A.; Billiet, C.; Defraene, G.; Peeters, S.; Draulans, C.; Nafteux, P.; Vansteenkiste, J.; Nackaerts, K.; Dooms, C.; Deroose, C.; Coolen, J.; De Ruysscher, D. Journal: Radiotherapy and oncology Issue: Volume 123:(2017:May)Supplement 1 Page Start: S667 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. EP-1246: Is there a different dose-effect relation between the tumour and involved lymph nodes in NSCLC?. (April 2016) Authors: Van den Bosch, L.; Defraene, G.; Peeters, S.; Dooms, C.; De Wever, W.; Deroose, C.; De Ruysscher, D. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S589 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. EP-1366: Different toxicity rating patients and physicians in randomized phase III PCI vs obs stage III NSCLC. (April 2018) Authors: De Ruysscher, D.; Dingemans, A.; Praag, J.; Belderbos, J.; Tissing-Tan, C.; Herder, G.; Haitjema, T.; Ubbels, F.; Lagerwaard, F.; Stigt, J.; Smit, E.; Van Tinteren, H.; Van der Noort, V.; Groen, H. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S745 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. EP-1367 Target volumes in adaptive treatment of NSCLC show large discrepancies among experts. (April 2019) Authors: Apolle, R.; Appold, S.; Bussink, J.; Faivre-Finn, C.; Khalifa, J.; Lievens, Y.; De Ruysscher, D.; Van Elmpt, W.; Troost, E.G.C. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S746 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗